Redhill Biopharma Announced The Publication Of Data, In Journal Microorganisms, From The Phase 2/3 Study Of Opaganib In Covid-19 Pneumonia That Showed 62% Reduction In Covid-19 Mortality
Portfolio Pulse from Benzinga Newsdesk
Redhill Biopharma published data from a Phase 2/3 study of Opaganib in COVID-19 pneumonia, showing a 62% reduction in mortality and a 21% improvement in time to room air. The study suggests FiO2 levels as a potential biomarker for disease severity.
September 03, 2024 | 11:14 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Redhill Biopharma's publication of positive Phase 2/3 study results for Opaganib in COVID-19 pneumonia could boost investor confidence and potentially increase stock prices.
The publication of positive clinical trial results is likely to enhance investor sentiment and could lead to a short-term increase in Redhill Biopharma's stock price. The significant reduction in mortality and improvement in recovery time are strong indicators of the drug's potential efficacy, which is crucial for investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100